Sagimet Biosciences Inc. Series A Common Stock SGMT · Stock Open Sagimet Biosciences Inc. Series A Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Sagimet Biosciences Inc. Series A Common Stock Analysis (SGMT)
Is Sagimet Biosciences Inc. Series A Common Stock a good investment? Sagimet Biosciences Inc. Series A Common Stock (SGMT) is currently trading at 8.02 USD. Market analysts have a consensus price target of 27.91 USD. This suggests a potential upside from current levels.
Earnings Schedule: Sagimet Biosciences Inc. Series A Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.30.
Investor FAQ
Does Sagimet Biosciences Inc. Series A Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Sagimet Biosciences Inc. Series A Common Stock?
Sagimet Biosciences Inc. Series A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.27.
Company Profile
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Community Discussion